Akèy › Kansè pwostat › Ohio › Cleveland
Etid klinik pou Kansè pwostat nan Cleveland, OH
34 etid pou Kansè pwostat ap chèche patisipan nan sit nan ak bò kote Cleveland (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- The Cleveland Clinic Taussig Cancer Center, Cleveland
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Ap rekriteFaz 3
- MetroHealth Medical Center, Cleveland
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Ap rekriteFaz 2
- MetroHealth Medical Center, Cleveland
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
Ap rekriteFaz 2
- Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Cente, Cleveland
Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
Ap rekrite
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Ap rekriteFaz 3
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Ap rekriteFaz 1
- University Hospitals Cleveland Medical Center, Cleveland
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Ap rekriteFaz 3
- University Hospitals Cleveland Medical Center, Cleveland
- UH Minoff Health Center at Chagrin Highlands, Orange · 12 mi lwen
- University Hospitals Seidman Cancer Center at UH Mentor Health Center, Mentor · 22 mi lwen
MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA)
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland
Investigation of Impact of AI on Prostate Cancer Workflow
Ap rekrite
- Cleveland Clinic Foundation, Cleveland
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
Ap rekrite
- University Hospitals Cleveland, Cleveland
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Ap rekriteFaz 3
- Case Western Reserve University, Cleveland
- Louis Stokes Cleveland VA Medical Center, Cleveland
- MetroHealth Medical Center, Cleveland
- ak 5 plis
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Louis Stokes Cleveland VA Medical Center, Cleveland
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Ap rekriteFaz 3
- Research Site, Cleveland
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ap rekriteFaz 2
- University Hospitals Cleveland Medical Center, Cleveland
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound
Ap rekrite
- Glickman Urological & Kidney Institute, Cleveland Clinic Foundation, Case Comprehensive Cancer Center, Cleveland
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Ap rekriteFaz 3
- Case Western Reserve University, Cleveland
- MetroHealth Medical Center, Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- ak 5 plis
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
Ap rekriteEtid obsèvasyon
- Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
Ap rekriteFaz 1
- Cleveland Clinic Foundation, Cleveland
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Ap rekriteFaz 4
- Cleveland Clinic Foundation, Cleveland
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Ap rekriteFaz 1/2
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Ap rekriteEtid obsèvasyon
- University Hospitals Cleveland Medical Center, Cleveland
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Ap rekriteFaz 1
- Research Site, Cleveland
Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
Ap rekrite
- UH Cleveland Medical Center, Cleveland
Cleveland African American Prostate Cancer Project
Ap rekriteVolontè an sante akeyi
- Barbershops Local to Cleveland, Cleveland
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Ap rekriteFaz 2/3
- Louis Stokes VA Medical Center, Cleveland, OH, Cleveland
Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
Ap rekrite
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Cleveland Clinic, Cleveland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Mayfield Heights · 12 mi lwen
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ap rekriteFaz 3
- MetroHealth Medical Center, Cleveland
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Exelixis Clinical Site #7, Cleveland
Etid Kansè pwostat nan lòt vil
- New York City, NY103 etid
- Houston, TX76 etid
- Los Angeles, CA61 etid
- Boston, MA59 etid
- St. Louis, MO46 etid
- Chicago, IL45 etid
- San Francisco, CA45 etid
- Philadelphia, PA44 etid
- Baltimore, MD43 etid
- Nashville, TN42 etid
- Seattle, WA42 etid
- Washington, DC38 etid
Lòt etid nan Cleveland
- Kansè Poumon ki pa ti selil43 etid
- Kansè (tout kalite)36 etid
- Kansè nan tete35 etid
- Ensifizyans kadyak33 etid
- Kansè Metastatik30 etid
- Kansè ovè30 etid
- Kansè poumon26 etid
- Kansè kolorektal24 etid
- Maladi kadyovaskilè22 etid
- Kansè Endomèt20 etid
- Leksemi mieloïd egi20 etid
- Maladi Crohn19 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.